,,ii #aacth ,,congress #ast ,session ,s4 #geb ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,april #ag1 #bjac ,mrs4 ,gillibrand introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to require the ,secretary of ,health and ,human ,services to promulgate regulations regarding the authorship1 content1 format1 and dissemination of ,patient ,medication ,information to ensure patients receive consistent and high-quality information about their prescription medications and are aware of the potential risks and benefits of prescription medications4 #a4 ,short title ,this ,act may be cited as the ,cody ,miller ,initiative for ,safer ,prescriptions ,act4 #b4 ,patient medication information for prescription drugs ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cea et seq47 is amended by inserting after section #eje;,e the following3 #eje;,f4 ,patient medication information for prescription drugs 7a7 ,in general ,not later than #b years after the date of enactment of this section1 the ,secretary shall issue regulations regarding the authorship1 content1 format1 and dissemination requirements for patient medication information 7referred to in this section as ,,pmi7 for drugs subject to section #ejc7;b77#a74 7b7 ,content ,the regulations promulgated under subsection 7a7 shall require that the ,,pmi with respect to a drug-- 7#a7 be scientifically accurate and based on the professional labeling approved by the ,secretary and authoritative1 peer-reviewed literature2 and 7#b7 includes nontechnical1 understandable1 plain language that is not promotional in tone or content1 and contains at least-- 7,a7 the established name of drug1 including the established name of such drug as a listed drug 7as described in section #eje7;j77#b77;,a77 and as a drug that is the subject of an approved abbreviated new drug application under section #eje7;j7 or of an approved license for a biological product submitted under section #cea7k7 of the ,public ,health ,service ,act1 if applicable2 7,b7 drug uses and clinical benefits2 7,c7 general directions for proper use2 7,d7 contraindications1 common side effects1 and most serious risks of the drug1 especially with respect to certain groups such as children1 pregnant women1 and the elderly2 7,e7 measures patients may be able to take1 if any1 to reduce the side effects and risks of the drug2 7,f7 when a patient should contact his or her health care professional2 7,g7 instructions not to share medications1 and1 if any exist1 key storage requirements1 and recommendations relating to proper disposal of any unused portion of the drug2 and 7,h7 known clinically important interactions with other drugs and substances4 7c7 ,timeliness1 consistency1 and accuracy ,the regulations promulgated under subsection 7a7 shall include standards related to-- 7#a7 performing timely updates of drug information as new drugs and new information becomes available2 7#b7 ensuring that common information is applied consistently and simultaneously across similar drug products and for drugs within classes of medications in order to avoid patient confusion and harm2 and 7#c7 developing a process1 including consumer testing1 to assess the quality and effectiveness of ,,pmi in ensuring that ,,pmi promotes patient understanding and safe and effective medication use4 7d7 ,electronic repository ,the regulations promulgated under subsection 7a7 shall provide for the development of a publicly accessible electronic repository for all ,,pmi documents and content to facilitate the availability of ,,pmi4 4 #c4 ,publication on internet website ,the ,secretary of ,health and ,human ,services shall publish on the ,internet website of the ,food and ,drug ,administration a link to the ,daily ,med website 7http3_/_/dailymed4nlm4nih4gov_/dailymed 7 7or any successor website74